11
11 Multidisciplinary care, follow-up, patient care
Pages 69–74 · open in PDF
Recommendations in this section
- Class ILevel B1A multidisciplinary HF management programme is recommended in patients with HF to reduce the risk of HFH and death.
- Class ILevel AHF education and self-management strategies in patients with HF are recommended to reduce the risk of HFH or death.
- Class ILevel B2Multidisciplinary interventions to improve adherence, including assessment of health literacy and polypharmacy review, are recommended in patients with HF to reduce the risk of hospitalization and death.
- Class ILevel B1Personalized exercise training, in the context of multidisciplinary exercise-based cardiac rehabilitation, is recommended for all stable patients, unless there are specific contraindications, in order to improve exercise capacity and QoL, and reduce the risk of all-cause hospitalization.
- Class ILevel B2Personalized exercise training outside exercise-based cardiac rehabilitation is recommended for all stable patients on a long-term basis, unless there are specific contraindications, in order to improve exercise capacity and QoL, and reduce the risk of
- Class ILevel B1Cardiac rehabilitation is recommended in patients with an LVAD to improve functional capacity and QoL.
- Class IIaLevel B1Cardiac rehabilitation should be considered in patients with DHF, as soon as safely possible, to improve functional capacity and QoL.
- Class IIaLevel B1Remote haemodynamic monitoring of PA pressure should be considered in symptomatic patients with HF, NYHA class III, and an HFH in the past 12 months in order to reduce the risk of HFH.
- Class IIbLevel B1Non-invasive telemonitoring modalities may be considered for patients with HF in order to reduce the risk of HFH.
- Class ILevel B1Proactive discussion regarding HF trajectory, goals of care, and advance care planning is recommended in patients with advanced HF to facilitate communication on end of life and QoL.
- Class ILevel B2Access to an integrated HF palliative care multidisciplinary team is recommended for patients in an advanced HF stage to improve QoL and reduce symptom burden.
Text below is machine-extracted from the PDF page(s) listed; two-column layouts and tables can read out of order, and neighbouring sections on the same page are included. Use the PDF link for the authoritative layout.
Page 69 · PDF
10.9. Other non-cardiovascular comorbidities Infections may cause WHF and can precipitate HFH.925,926 Infections should ideally be prevented or, if present, promptly recognized and treated to avoid disease progression.927–930 Influenza vaccination is associated with a reduced risk of pneumonia and all-cause death in patients with HF.931–936 Thus, influenza and pneumococcal vaccination should be considered in all patients with HF in order to reduce the risk of infection-related complications.935 Thyroid dysfunction can cause changes in cardiac function and structure and may precipitate DHF.937,938 Assessment of thyroid function is recommended in patients with de novo HF or DHF and should be regularly assessed during follow-up of patients with HF. Treatment of thyroid dysfunction should be guided by endocrine guidelines.939–942 Hyperuricaemia and consequent gout attacks can be frequent in patients with HF, mainly caused or precipitated by diuretic treatment.943,944 Allopurinol is recommended as the first choice to chronically reduce uric acid levels in patients with HF,945 whereas colchicine can be used for acute gout attacks. Non-steroidal antiinflammatory drugs and selective cyclooxygenase-2 inhibitors are not recommended in patients with HF because they may precipitate decompensation and worsen kidney function.942,946–948 Heart failure and erectile dysfunction frequently coexist.949,950 Cardioselective beta-blockers should be preferred in patients with HF and erectile dysfunction, mainly bisoprolol and nebivolol, started at the lowest doses.897 In the presence of erectile dysfunction symptoms, phosphodiesterase-V inhibitors are generally safe and can be considered in patients who are compensated,951 avoiding their concomitant use with nitrates.952 Recommendation Table 22 — Recommendations for other non-cardiovascular comorbidities (see Evidence Tables 92 and 93)
Influenza and pneumococcal vaccination should be considered in patients with HF to reduce the risk of pneumonia complications,
Recommendation Table 23 — Recommendations for the multidisciplinary management of heart failure (see Evidence Tables 94–96)
hospitalization, and death.
NSAIDs and COX-2 inhibitors are not recommended in patients with HF as they increase the risk of HF worsening and
HFH.942,946–948 COX-2, cyclooxygenase-2; HF, heart failure; HFH, heart failure hospitalization; NSAID, non-steroidal anti-inflammatory drug. a Class of recommendation. b Level of evidence.
11. Multidisciplinary team management, long-term follow-up, and patient care 11.1. Multidisciplinary management of heart failure Multidisciplinary care for HF combines the expertise of various professionals to provide integrated, patient-centred care that
Recommendations A multidisciplinary HF management programme is recommended in patients with HF to reduce the risk of HFH and
death.964–967 HF education and self-management strategies in patients with HF are recommended to reduce the risk of HFH or death.977 Multidisciplinary interventions to improve adherence, including assessment of health literacy and polypharmacy review, are recommended in patients with HF to reduce the risk of hospitalization and death.978–981 HF, heart failure; HFH, heart failure hospitalization. a Class of recommendation. b Level of evidence.
improves both clinical outcomes and QoL for patients (Figure 21). Access to healthcare professionals with awareness of HF and expertise in its diagnosis and management is essential for early detection and better outcomes. Multidisciplinary HF care involves generalist and specialist healthcare professionals,955 including cardiologists, cardiothoracic surgeons, specialist nurses, pharmacists, and physiologists (Figure 21) (see Supplementary data online, Section S8.1).17,956–963 Management by an HF multidisciplinary team (HF-MDT) across outpatient and inpatient settings improves outcomes for people with HF.962,964–967 The literature evaluates various methods of delivering HF management programmes enabling local HF services to design services tailored to their HF-MDT and the structure of their healthcare system. A meta-analysis of 16 RCTs with 3999 eligible patients evaluating the benefits of multidisciplinary HF clinics compared with usual care demonstrated a reduction in HFH.967 A meta-analysis of eight RCTs with 1764 patients indicated that multidisciplinary teams may have the potential to reduce death, although a definitive RCT is needed.964 The benefits were more evident in patients with a recent emergency department presentation or HFH.966 Other methods of delivery, including home visits and transitional care models, are given in Supplementary data online, Section S8.1.145,962,965,968–972 Healthcare professionals involved in the management of HF, whether specialist or generalist, should be equipped with the knowledge required to effectively assess and manage HF through appropriate education and training.958,973,974 Malnutrition has been associated with worse prognosis in patients with HF.738 Thus, nutritional assessment and dietary interventions can be useful.588,589 No evidence supports fluid restriction in chronic HF.975,976
Page 70 · PDF
Figure 21 Core members of the heart failure team with expanded team members depending on patient needs and local availability. AP, allied professional; EP, electrophysiology; HF, heart failure.
Page 71 · PDF
11.4. Exercise training and cardiac rehabilitation
Education, self-care, and lifestyle advice empower patients and their caregivers in managing HF and engage in shared decisionmaking. Self-care incorporates education and strategies to support maintenance, monitoring, and management of HF.973 The aim is to ensure people with HF and their caregivers are equipped with knowledge and skills and be partners in their care and not simply recipients of information and treatments. The benefits of self-care are described in a meta-analysis of 20 RCTs including 5624 patients.977 Self-management interventions on the background of usual HF care improved QoL and reduced time to HFH or all-cause death. There may be some barriers to self-care, but these can be overcome by careful design of programmes982,983 (see Supplementary data online, Section S8.2). Effective self-care enhances QoL, reduces symptom severity, and lowers the risk of hospitalization. It is essential that HF professionals collaborate with patients and caregivers, using shared decision-making to develop personalized self-care plans (Supplementary data online, Table S24).
11.4.1. Benefits of exercise training according to heart failure stage and phenotype
11.3. Implementation and adherence to therapy 11.3.1. Implementation and optimization Implementation of HF therapies should be individualized, based on available evidence, and involve the HF-MDT and patients and caregivers. Yet, there remain delays to implementation and optimization of treatments.984–986 Multivariable adjusted large observational studies suggest that among the strongest factors associated with improved FMT, AMT, and GDIT use is access to cardiologist specialists.987–990 For barriers and facilitators to improved implementation of HF therapies, including clinical inertia, impact of race, ethnicity, gender, and health literacy, see Supplementary data online, Table S25. Evidence supports the role of HF nurses and pharmacists in the implementation and optimization of HF therapies and avoidance of unnecessary side effects of polypharmacy.991–994 Pharmacists play a key role in ensuring safe and effective use of medicines, including medication reconciliation and the optimization of therapies for comorbidities. Development of the HF-MDT to support the implementation and optimization of HF and to address the barriers that exist is key to improving outcomes for patients.
11.3.2. Long-term adherence Adherence to self-care strategies and therapies is essential to control symptoms, limit disease progression, and reduce hospitalization and death.981 Factors that impact adherence and affect clinical outcomes include health literacy, polypharmacy, and managing multiple health conditions.978,979,995 Strategies to improve adherence in the context of HF have been described elsewhere and provide guidance on the use of education tailored to the individual, communication skills, polypharmacy review, and co-ordinated care.980,996 Central to these is the importance of the HF-MDT recognizing the barriers to adherence, assessing those barriers, and utilizing other members of the health and social care team to address them.
There is consistent evidence that exercise training improves exercise tolerance and health-related QoL in patients with HF.94 HF-ACTION was the largest RCT on exercise training in HF including 2331 patients with LVEF ≤35% (NYHA classes II–IV). Compared with usual care, supervised exercise training plus usual care showed modest, non-significant reductions in allcause death and hospitalizations. However, prespecified adjustments revealed significant reductions in CV death and HFH.997 A systematic review of 60 trials with 8728 patients (mean age 63 years, mean LVEF 32%) confirmed improvements in functional capacity, QoL, and reductions in HFH with exercise training but found no reduction in death.998 Similar findings were reported by another systematic review focusing on HFrEF (LVEF <40%).94,999 In HFpEF, exercise training is safe and significantly enhances exercise capacity and QoL, with no significant impact on diastolic function, arterial stiffness, or vascular function, and insufficient data exist to assess its impact on clinical events, such as death and hospital admissions, due to small sample sizes and short follow-up times.1000,1001 Most trials in HF, except for HF-ACTION, are too small to reliably evaluate the effects of exercise rehabilitation across subgroups (see Supplementary data online, Section S8.4).1002,1003 In patients with long-term mechanical support, the benefit of exercise training on functional capacity has been demonstrated.1004,1005 The Rehab-VAD trial showed that moderate intensity aerobic training was safe in patients with continuousflow LVADs and yielded significantly improved health status, treadmill time, and leg strength, without significant improvements in peak oxygen consumption.1006 If a patient with advanced HF can tolerate physical activity, exercise training can improve QoL.1007 Exercise training before and after heart transplantation should follow recommendations according to the consensus document.1008
11.4.2. Safety and contraindications No major adverse effects of exercise training were reported in the included studies of above systematic reviews and meta-analyses.1001,1009 However, exercise interventions should only be initiated in stable individuals after initiation of FMT. Exercise training is contraindicated in patients with refractory/unstable angina and other high-risk CV conditions (e.g. high-grade arrhythmias, DHF, active thromboembolic disease) and in any other unstable non-cardiac condition (e.g. active infection, uncontrolled diabetes, end-stage cancer, COPD exacerbation).94
11.4.3. Exercise prescription A personalized training programme, with the mode of delivery, type, and intensity tailored to the patient’s preferences, risk level, and comorbidities, is recommended to improve uptake of exercise-based cardiac rehabilitation. Exercise training should be started as part of cardiac rehabilitation and be individually prescribed according to the FITT model (frequency, intensity,
11.2. Patient education, self-care, and lifestyle advice
Page 72 · PDF
time, type) for aerobic training, resistance training, and inspiratory muscle training1010,1011 (see Supplementary data online, Section S8.4).998,1012–1016 Adherence to the prescribed exercise regimen is crucial (see Supplementary data online, Section S8.4).1017–1020 Recommendation Table 24 — Recommendations for exercise training and cardiac rehabilitation (see Evidence Tables 97–99) Recommendations
Personalized exercise training, in the context of multidisciplinary exercise-based cardiac rehabilitation, is recommended for all stable patients, unless there are specific contraindications, in order to improve exercise capacity and QoL, and reduce the risk of all-cause hospitalization.1021 Personalized exercise training outside exercise-based cardiac rehabilitation is recommended for all stable patients on a long-term basis, unless there are specific contraindications, in order to improve exercise capacity and QoL, and reduce the risk of all-cause hospitalization.1022 Cardiac rehabilitationc is recommended in
Recommendation Table 25 — Recommendations for invasive and non-invasive telemonitoring (see Evidence Table 100)
Cardiac rehabilitationc should be considered in patients with DHF, as soon as safely possible, to improve functional capacity and QoL.1002,1024– 1026
DHF, decompensated heart failure; LVAD, left ventricular assist device; QoL, quality of life. a Class of recommendation. b Level of evidence. c Either comprehensive or exercise-based.
capacity and QoL.1005,1023
Advances in digital technology and telemonitoring have, in recent years, contributed substantially to the transformation of (remote) care delivery, from a hospital-centred approach to a patient-oriented approach. Telemonitoring can involve non-invasive and invasive monitoring modalities. Non-invasive telemonitoring relies on traditional vital parameters measured remotely (e.g. weight, heart rate, and blood pressure), which can be used to guide patients remotely to adjust therapy or seek advice either through telephone consultations or eHealth-based environments. Recent systematic reviews and meta-analyses report significant reductions in all-cause death and HFH with non-invasive telemonitoring.1027–1029 However, despite a growing body of evidence, results from individual trials are inconsistent and limited mainly by considerable heterogeneity in terms of patient population, modality, and intervention (see Supplementary data online, Section S8.5).1027–1031 At present, non-invasive telemonitoring may be considered for patients with HF in order to reduce the risk of HFH.
Remote haemodynamic monitoring of PA pressure should be considered in symptomatic patients with HF, NYHA class III, and an HFH in the past 12 months in order to reduce the risk of HFH.1029,1043,1045 Non-invasive telemonitoring modalities may be considered for patients with HF in order to reduce the risk of HFH.1027,1029,1053
HF, heart failure; HFH, heart failure hospitalization; NYHA, New York Heart Association; PA, pulmonary artery. a Class of recommendation. b Level of evidence.
11.6. Long-term follow-up 11.6.1. Follow-up Patients with HF, even when symptoms are stable and well controlled, require regular in-person follow-up to ensure ongoing optimization of therapy, detect asymptomatic disease progression or comorbidities, and discuss new advances in care. For follow-up intervals of patients with a recent episode of DHF undergoing optimization or uptitration of FMT, see Section 7. For symptomatic patients with HF with no recent DHF, these guidelines recommend assessment of symptom severity, pharmacological adherence, arrhythmias, changes in the ECG and, if deemed relevant, echocardiography and laboratory parameters (including full blood count, electrolytes, iron
patients with an LVAD to improve functional
Device-based monitoring modalities (pacemaker/ICD/CRT) based upon thoracic impedance, heart sounds, and breathing patterns, aim to assist in the selection between stable patients and those that need rapid access to care.1032,1033 Many implanted devices can provide remote information either on the device itself (generator and lead function), arrhythmias, or on patient physiology (heart rate, heart sounds, bio-impedance). There is evidence that monitoring can detect device malfunction/integrity and that it may be useful for detecting arrhythmias. However, there is currently little evidence that device monitoring improves clinical outcomes, although ongoing RCTs are awaited.1029,1033–1039 Invasive monitoring modalities consist of several specifically designed telemonitoring sensor technologies measuring remote haemodynamic parameters. Currently, only pulmonary artery sensor-guided therapy has been studied in multiple RCTs and has shown a benefit in reducing HFH in patients in NYHA class III and a HFH within the past 12 months.1029,1040–1047 Additionally, several prospective studies have confirmed the safety and efficacy of pulmonary artery-guided therapy in reducing HFH in multiple settings.1037,1048–1052 Remote haemodynamic monitoring by pulmonary artery-guided therapy should be considered in selected patients with moderate-to-severe HF with NYHA class III and a HFH within the past 12 months in order to reduce the risk of HFH.
Page 73 · PDF
Symptomatic heart failure
Advanced heart failure
Figure 22 Long-term follow-up of patients with stable heart failure—what—when—who. CIED, cardiac implantable electronic device; CPET, cardiopulmonary exercise testing; ECG, electrocardiogram; HF, heart failure; HF-MDT, heart failure multidisciplinary team; RHC, right heart catheterization. aIf deemed clinically relevant. bCheck ‘I NEED HELP’ criteria, Figure 16; Table 15 (Section 8). c Intervals may be shorter.
status, liver, kidney, and thyroid function). What is needed, at which interval and who has to perform the follow-up assessment depend on HF stage (Figure 22). The necessity of cardiologist-led follow-up for these patients remains uncertain, with some studies suggesting that primary care follow-up may be appropriate.1054 However, evidence-based intervention uptake is low in many settings, and studies indicate that follow-up by an HF clinic, alongside quality improvement registries, may lead to better therapy optimization and improved outcomes.990,994,1054–1057 An ECG is recommended to detect QRS prolongation, which may qualify patients for CRT, as well as to identify conduction disturbances, AF, and other arrhythmias. Echocardiography should be performed if there is clinical deterioration or if otherwise deemed relevant. Trials investigating the use of biomarkers, such as BNP and NT-proBNP, to guide therapy in HFrEF have yielded inconsistent results.1058–1060 Although these biomarkers are strong prognostic indicators, it remains unclear what additional value a biomarker-guided strategy offers beyond strict adherence to FMT. As such, routine biomarker measurement for guidance on diuretic therapy is not currently supported by the evidence.
11.6.2. Advance care planning and palliative care While the disease trajectory of each patient with HF is unique, there is a generalizable pattern of gradual decline, punctuated by episodes of acute deterioration leading to death. Communication about disease trajectory and advance care planning should be incorporated by all healthcare professionals throughout the course of the disease.1061,1062 Advance care planning is a structured process that facilitates the exploration and communication of the patient’s personal values, life goals, and preferences regarding future medical care, and may include preferences for place of death and resuscitation (which may include deactivating devices, such as ICD or durable MCS). Advance care planning should be documented, regularly reviewed, and routinely communicated to all those involved in the patient’s care. Evidence shows that proactive advance care planning can reduce hospitalizations and improve QoL and end-of-life care, yet many patients with HF lack formalized plans, highlighting the need for better implementation.627 Palliative care, defined as patient- and family-centred care aimed at optimizing health-related QoL by anticipating, preventing, and alleviating suffering, should be integrated into the management of patients with HF in an advanced stage of the
At risk for heart failure
Page 74 · PDF
disease. The role of palliative and supportive care spans the entire course of HF, beginning early in the disease, intensifying as the condition progresses, and extending into caregiver bereavement. Evidence supports the use of multidisciplinary palliative care in people with advanced HF to improve patient-reported outcomes (symptom burden, depression, functional status, QoL), but trials do not identify who would benefit most from specialist palliative referral.1063–1065 There are no sufficiently robust multicentre evaluation phase trials to provide generalizable findings.
In pregnant women with HFrEF, it is recommended that non-selective beta-blockers are switched to beta1-selective blockers (metoprolol, bisoprolol) with close mother and
teratogenicity.1074–1076 ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; MRA, mineralocorticoid receptor antagonist; SGLT2-I, sodium–glucose co-transporter 2 inhibitor. a Class of recommendation. b Level of evidence.
QoL and reduce symptom burden.1066–1068 HF, heart failure; QoL, quality of life. a Class of recommendation. b Level of evidence.
12.2.1. Hypertrophic cardiomyopathy Patients with HCM may develop HFrEF; in such cases, they should in general be treated as other patients with HFrEF. However, many patients develop symptoms of HF without having HFrEF, and these should be treated according to the cardiomyopathy guidelines (see Supplementary data online, Section S9.2).124
12. Specific conditions 12.1. Pregnancy and heart failure Heart failure in pregnancy requires careful multidisciplinary management.1069–1071 The core components of HF care in pregnancy involves multiple aspects from pre-conception to postpartum (see Supplementary data online, Table S26). Specific recommendations for pre-conception care and management of HF during pregnancy can be found in Recommendation Table 27. For an overview of managing HF in pregnancy, see Supplementary data online, Section S9.1. For a comprehensive and detailed guidance, we refer to the 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy.7
Recommendation Table 27 — Recommendations for heart failure and pregnancy (see Evidence Tables 103–107) Recommendations
Pre-conception care and counselling is recommended for patients with HF to facilitate decision-making surrounding HF treatments, pregnancy, contraception, pre-implantation genetic screening, and assisted reproductive
patients in an advanced HF stage to improve
Cardiomyopathies are a common and specific cause of HF.124 The 2023 ESC Guidelines for the management of cardiomyopathies described cardiomyopathy phenotypes based on structural (e.g. ventricular hypertrophy, dilatation, or scar) and functional (e.g. systolic or diastolic dysfunction) features.124 Detailed recommendations and algorithms for the diagnosis and management of cardiomyopathies are provided in the 2023 ESC Guidelines for the management of cardiomyopathies.124
12.3. Amyloidosis 12.3.1. Epidemiology and diagnosis Cardiac amyloidosis is an infiltrative cardiomyopathy caused by amyloid fibril deposition in the extracellular space, resulting in increased myocardial thickness and stiffness, leading to a restrictive physiology.1077,1078 The two most prevalent forms of CA are immunoglobulin light chain CA (AL-CA) and transthyretin amyloidosis (ATTR). Transthyretin amyloidosis includes the wild-type (>90% of cases), and the hereditary or variant forms.1077 Greater awareness of CA, streamlined diagnostic processes, and the emergence of new treatments has led to an increase in the prevalence of CA.1079,1080 The prevalence of CA is higher in males.1081 Cardiac amyloidosis should be suspected in patients with HF and increased LV wall thickness in the presence of specific red flags (Table 20), particularly in patients aged >65 years. A timely, definitive diagnosis should be obtained as patient outcomes depend largely on early initiation of therapy (particularly in AL-CA). Cardiac amyloidosis can be diagnosed using both invasive and non-invasive diagnostic criteria. Invasive diagnostic criteria apply to all forms of CA, whereas non-invasive criteria are accepted only for transthyretin CA (ATTR-CA).1077 Figure 23 displays the diagnostic work-up and treatment options. For more diagnostic details, the Task Force refers to the 2021 ESC position statement on CA.1077
SGLT2-Is are not recommended during pregnancy due to the risk of foetotocixity or
facilitate communication on end of life and QoL.627 Access to an integrated HF palliative care multidisciplinary team is recommended for
ACE-Is, ARBs, ARNIs, MRAs, ivabradine, and
Proactive discussion regarding HF trajectory, goals of care, and advance care planning is recommended in patients with advanced HF to
foetal events and a lower birth weight.1072,1073
foetus monitoring to reduce the risk of adverse
Recommendation Table 26 — Recommendations for longterm follow-up (see Evidence Tables 101 and 102) Recommendations